Professor Thomas Rademacher
CEO and CSO
Professor Rademacher co-founded Emergex Vaccines and has served as CEO and CSO since the Company’s formation.
He is an Emeritus Professor of Molecular Medicine at University College London and a serial entrepreneur. He co-founded Oxford GlycoSciences, the first of Oxford University’s biotech spin-outs, which, in 1998, was listed on the London Stock Exchange, reached a market capitalisation of £1.7 billion. After moving to UCL, Professor Rademacher founded several biotech spin-out companies, including Rodaris Pharmaceuticals Ltd.
In 2000, he entered into a collaboration with the Spanish Research Council and founded Midatech Ltd as a spin-out of the Consejo Superior de Investigationes Cientificas (CSIC). This expanded his portfolio of company start-ups into the field of nanomedicine, in which Professor Rademacher holds 19 patents, including being an author on the Midatech nanoparticle patents which have been licensed by Emergex. Midatech floated on the AIM and NASDAQ stock exchanges in December 2015.
Professor Rademacher has authored over 200 publications and 50 patents. In addition to being a world leader in nanomedicine, he is also an expert in foetal-maternal medicine, having produced 25 publications and filed 5 patents related to preeclampsia.